

## **Fulcrum Therapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Monday, May 15, 2023, at 8:00 a.m. ET**

May 8, 2023 at 4:07 PM EDT

CAMBRIDGE, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.<sup>®</sup> (the "Company") (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its first quarter 2023 financial results will be released on Monday, May 15, 2023 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.

Individuals may register for the conference call by clicking the link [here](#). Once registered participants will receive a dial and unique PIN which will allow them to access the call. An audio webcast will be accessible through the Investor Relations section of the company's website at [www.fulcrumtx.com](http://www.fulcrumtx.com) or by clicking [here](#). Following the live webcast, an archived replay will also be available.

### **About Fulcrum Therapeutics**

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum's two lead programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD) and other hemoglobinopathies, which is currently under a clinical hold issued by the U.S. Food and Drug Administration. The company's proprietary product engine, FulcrumSeek<sup>™</sup>, identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit [www.fulcrumtx.com](http://www.fulcrumtx.com) and follow us on Twitter [@FulcrumTx](#) and [LinkedIn](#).

### **Contact:**

#### Investors:

Chris Calabrese  
LifeSci Advisors, LLC  
[ccalabrese@lifesciadvisors.com](mailto:ccalabrese@lifesciadvisors.com)  
917-680-5608

#### Media:

Dee Smith  
Executive Director, Corporate Communications  
Fulcrum Therapeutics, Inc.  
[dsmith@fulcrumtx.com](mailto:dsmith@fulcrumtx.com)  
202-746-1324